RetroSense Therapeutics’ Lead Gene Therapy Candidate Gets FDA Clearance to Proceed to First-in-Human Clinical Trials

ANN ARBOR, Mich.--(BUSINESS WIRE)--RetroSense Therapeutics announced an Investigational New Drug (IND) application for RST-001 received clearance from the FDA. RetroSense is developing RST-001 for the treatment of retinitis pigmentosa